Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: Results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations

Journal of Clinical Rheumatology

Volumn 20, Issue 5, 2014, Pages 256-260

  Freundlich, Bruce ^a,b   Kivitz, Alan ^c   Jaffe, Jonathan S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Clinical Development Antares Pharma Inc   (United States)

^c Altoona Center for Clinical Research   (United States)

Author keywords

Methotrexate; Pain; Rheumatoid arthritis; Selfadministration; Subcutaneous

Indexed keywords

METHOTREXATE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; AUTOINJECTOR; CONTROLLED STUDY; DISEASE DURATION; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TREATMENT DURATION; VISUAL ANALOG SCALE; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DEVICES; DISABILITY; DOSE RESPONSE; DRUG ADMINISTRATION; EQUIPMENT DESIGN; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PAIN MEASUREMENT; PROCEDURES; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT DESIGN; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; MIDDLE AGED; PAIN MEASUREMENT; SELF ADMINISTRATION; SEVERITY OF ILLNESS INDEX; SYRINGES; TREATMENT OUTCOME;

EID: 84905111054     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000117     Document Type: Article

References (21)

1. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.
2. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625-639.
3. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086-1093.
4. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature. Ann Rheum Dis. 2009;68:1094-1099.
5. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645-648.
6. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997;36:86-90.
7. Schiff MH, Simon LS, Freundlich B, et al. Drug exposure limitations of oral methotrexate (MTX) at doses 915mgs may be overcome by using a subcutaneous MTX auto-injector in patients with rheumatoid arthritis (RA). Presented at the American College of Rheumatology Annual Meeting. San Diego, CA, 2013.
8. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Joint Dis. 2007;65:168-173.
9. Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989;16:313-320.
10. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232-1234.
11. Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis?. A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69:1849-1852.
12. Hameed B, Jones H. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2010;13:e83Ye84.
13. Mainman H, McClaren E, Heycock C, et al. When should we use parenteral methotrexate?. Clin Rheumatol. 2010;29:1093-1098.
14. Curtis JR, Xie F, Zhang J, et al. Patterns of use of oral and subcutaneous methotrexate use in rheumatoid arthritis patients enrolled in the U.S. Medicare program. Presented at the American College of Rheumatology Annual Meeting. San Diego, CA, 2013.
15. Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. 1999. Available at: Https://www.osha.gov/dts/osta/ otm/otm-vi/otm-vi-2.html. Accessed August 12, 2013.
16. Bedford Laboratories. Material safety data sheet. 2007. Available at: Http://www.bedfordlabs.com/content/dam/internet/opu/bedfordlabs/ com-EN/documents/products/Methotrexate/Methotrexate-Lyo-8-23- 05Rev07.pdf. Accessed August 12, 2013.
17. OTREXUP. Methotrexate Injection, for Subcutaneous Use. Ewing, NJ: Antares Pharma, Inc; 2013.
18. Katchamart W, Bourre-Tessier J, Donka T, et al. Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. J Rheumatol. 2010;37:1422-1430.
19. Phillips JT, Fox E, GraingerW, et al. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex\ prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011;11:126.
20. Ward LG, Aton SS. Impact of an interchange program to support use of insulin pens. Am J Health Syst Pharm. 2011;68:1349-1352.
21. Xie L, Zhou S, Wei W, et al. Does pen help?. A real-world outcomes study of switching from vial to disposable pen among insulin glargine-Treated patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2013;15:230-236.